Back to top

Analyst Blog

Calif.-based medical instruments maker Varian Medical Systems (VAR - Analyst Report) entered an agreement to acquire the Velocity software from Atlanta-based Velocity Medical Solutions, LLC. However, the news failed to entice investors as stock price stayed almost the same (just a 0.1% slide) since the announcement.

The Velocity software is designed to help clinicians making informed decisions for treating their patients by presenting a comprehensive view of a patient’s diagnostic imaging and treatment history, regardless of their previous location of treatment or previous technology used for the treatment. The software is capable of accessing and aggregating unstructured treatment and imaging data from diverse systems.

The privately-held Velocity Medical Solutions was founded by some eminent clinicians in order to transform unstructured data into meaningful clinical knowledge. The Velocity software has already been used at over 200 cancer treatment centers globally.

Post-acquisition, Varian expects its global sales, service and support network will lead to better market penetration for the Velocity software. The company intends to develop this oncology software platform with the Velocity team in Atlanta, GA. The acquisition is expected to close in the fiscal third quarter.

VAR posted a 5.8% rise in net earnings per share to 91 cents for the first quarter of fiscal 2014 from 86 cents in the prior fiscal quarter, and edged past the Zacks Consensus Estimate by a penny. With this, VAR also met its own guidance of a 6–7% rise in earnings per share to 87–91 cents for the quarter.

Revenues in the quarter escalated nearly 5.0% to $711.5 million during the quarter, but lagged the Zacks Consensus Estimate of $718 million. The growth was attributable to the continued strong demand for Oncology services and X-ray imaging components during the quarter.  

For fiscal 2014, VAR expects revenues to grow by 6–8% compared with the earlier guidance of 6–7%. However, the company reiterated its earnings per share guidance between $4.22 and $4.34 for the year. The current Zacks Consensus Estimate of $4.29 lies within the guided range.

For the second quarter of fiscal 2014, VAR expects revenues to be flat on a year-over-year basis. However, it expects earnings per share for the quarter in the range of $1.00 to $1.04. The current Zacks Consensus Estimate of $1.02 lies within the guided range.

Currently, VAR carries a Zacks Rank #3 (Hold). Some better-ranked medical instrument stocks that currently worth a look include Cynosure Inc. (CYNO - Snapshot Report), Syneron Medical Ltd. (ELOS - Snapshot Report), and DexCom, Inc. (DXCM - Analyst Report). Both Cynosure and Syneron Medical sport a Zacks Rank #1 (Strong Buy), while DexCom carries a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
GTT COMMUNI… GTT 11.65 +4.11%
ALLERGAN IN… AGN 161.82 +3.99%
CLAYTON WIL… CWEI 117.06 +3.73%
GREENBRIER… GBX 69.63 +2.37%
RF MICRO DE… RFMD 12.02 +2.04%